Screener
Cullinan Therapeutics, Inc. CGEM Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed November 7, 2024.
- Filed
- Nov 7, 2024
- Fiscal quarter
- Q3 FY2024
- Calendar quarter
- Q3 2024
- Accession
- 0000950170-24-122795
| Line item | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|---|---|---|---|---|
| Numerator: | ||||
| Net loss attributable to common stockholders of Cullinan | $(40,560) | $(39,183) | $(119,736) | $(129,359) |
| Denominator: | ||||
| Weighted-average common stock outstanding — basic and diluted | 58,337 | 42,734 | 52,157 | 41,130 |
| Net loss per share attributable to common stockholders of Cullinan: | ||||
| Basic and diluted | $(0.69) | $(0.91) | $(2.30) | $(3.15) |
Item 1. Financial Statements.
FAQ
- What is Cullinan Therapeutics, Inc.'s shares (diluted)?
- Cullinan Therapeutics, Inc. (CGEM) reported shares (diluted) of 58.3M in Q3 2024.
- How has Cullinan Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Cullinan Therapeutics, Inc.'s shares (diluted) increased by 36.5% year-over-year, from 42.7M to 58.3M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s shares (diluted)?
- Over 2 years (2021 to 2023), Cullinan Therapeutics, Inc.'s shares (diluted) has grown at a -2.0% compound annual growth rate (CAGR), from 171.8M to 164.9M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Cullinan Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude